Flutamide is a nonsteroidal antiandrogen (NSAA) which is used to treat the prostate cancer by blocking the action of exogenous testosterone thru binding to the androgen receptor. This study was designed and performed to investigate the impact of The Trivedi Effect®-Biofield Energy Healing Treatment on the structural properties and isotopic abundance ratio of flutamide using LC-MS and GCMS spectroscopy. Flutamide sample was divided into two parts, one part of flutamide was considered as control (no Biofield Energy Treatment was provided), while the second part was treated with The Trivedi Effect®-Consciousness Energy Healing Treatment remotely by a renowned Biofield Energy Healer, Alice Branton and termed as a treated sample. The LC-MS spectra of both the samples at retention time (Rt) 3.4 minutes exhibited the mass of the deprotonated molecular ion peak at m/z 275.08 [M-H]- (calculated for C11H10F3N2O3-, 175.06). The LC-MS based isotopic abundance ratio of PM+1/PM (2H/1H or 13C/12C or 15N/14N or 17O/16O) in the treated flutamide was significantly increased by 18.44% compared with the control sample. Thus, 13C, 2H, 15N, and 17O contributions from (C11H10F3N2O3)- to m/z 276.08 in the treated sample were significantly increased compared with the control sample. The GC-MS based isotopic abundance ratio of PM+1/PM in the treated flutamide was increased by 4.72% compared with the control sample. Hence, 13C, 2H, 15N, and 17O contributions from (C11H10F3N2O3)+ to m/z 277 in the Biofield Energy Treated sample were significantly increased compared with the control sample. The isotopic abundance ratio of PM+1/PM (2H/1H or 13C/12C or 15N/14N or 17O/16O) in the treated flutamide was significantly altered compared to the control sample. It can be assumed that the changes in isotopic abundance and mass peak intensities could be due to changes in nuclei possibly through the interference of neutrino particles via the Trivedi Effect®- Consciousness Energy Healing Treatment. The new form of treated flutamide would be better designing novel pharmaceutical formulations that might offer better therapeutic response against prostate cancer, androgen-dependent skin and hair conditions including acne, seborrhea, hirsutism, and scalp hair loss, hyperandrogenism, as well useful for feminizing hormone therapy aimed at transgender women.
